[Hanoi, Vietnam] — [22nd March 2024] — In a groundbreaking move set to revolutionize the landscape of cancer care in Vietnam, AmoyDx, a leader in molecular testing for cancer together with BCE Vietnam had signed a Memorandum of Understanding (MOU) with the Vietnam Society of Pathology and Cytology (VSPC) to launch an independent educational initiative committed to Overseas Molecular Pathology Training.
"Precision oncology represents the future of cancer treatment, and with this initiative, we are making that future a reality for Vietnam," said Paul Huang, Senior Director of International Business at AmoyDx. "The MOU signing ceremony is not just a formality; it's a declaration of our united vision to improve cancer outcomes. "
From bottom right, Associate Prof. Trinh Tuan Dung, President of the VSPC; Paul Huang, Senior Director at AmoyDx; Ms. Thanh Tam,
Sales and Marketing Director at BCE Vietnam; From top right, Ms. Ngo Thi Ngoc Hoa, General Director of Tam Anh General Hospital;
Associate Prof. Ta Van To from Hanoi Medical University; Prof. Hua Thi Ngoc Ha from the University of Medicine and Pharmacy HCMC and James Chu, Senior Business Manager from AmoyDx
Key Highlights of the Initiative
Annual Overseas Molecular Pathology Training: Over the next 3 years, the VSPC will nominate top pathologists for an intensive three-month molecular pathology training program abroad where they will get the opportunity to learn and engage with global experts in the field.
Comprehensive Curriculum: An all rounded molecular pathology curriculum, covering both theoretical knowledge and its practical application in clinical settings. This will allow attendees to be exposed to international best practices as well as the ability to transfer valuable knowledge and experience back to the Vietnamese healthcare system.
About the Vietnam Society of Pathology and Cytology (VSPC): The VSPC is a professional organization dedicated to the advancement of pathology and cytology in Vietnam. It serves as a platform for Vietnamese pathologists and cytologists to exchange knowledge, foster professional development, and promote the highest standards of patient care in the field of pathology.
About AmoyDx: AmoyDx is at the forefront of championing molecular diagnostics for cancer, committed to enhancing patient outcomes worldwide through innovative diagnostic solutions and breaking barriers for global precision oncology adoption. The company is recognized for its excellence in precision medicine, driving advancements in cancer diagnosis through its extensive collaboration with pharmaceutical companies. For more information, please visit https://amoydiagnostics.com.
About BCE Vietnam: BCE Vietnam specializes in the distribution of life science, medical and diagnostic equipment, striving to introduce the latest healthcare innovations to the Vietnamese market. The company is dedicated to improving the quality of healthcare in Vietnam through state-of-the-art technologies and services. For more information, please visit https://bcevietnam.com.vn
For media inquiries, please contact:
Robson Ee
Director, International Business
AmoyDx(Singapore) PTE LTD
info@amoydiagnostics.com
https://www.amoydiagnostics.com
"Precision oncology represents the future of cancer treatment, and with this initiative, we are making that future a reality for Vietnam," said Paul Huang, Senior Director of International Business at AmoyDx. "The MOU signing ceremony is not just a formality; it's a declaration of our united vision to improve cancer outcomes. "
From bottom right, Associate Prof. Trinh Tuan Dung, President of the VSPC; Paul Huang, Senior Director at AmoyDx; Ms. Thanh Tam,
Sales and Marketing Director at BCE Vietnam; From top right, Ms. Ngo Thi Ngoc Hoa, General Director of Tam Anh General Hospital;
Associate Prof. Ta Van To from Hanoi Medical University; Prof. Hua Thi Ngoc Ha from the University of Medicine and Pharmacy HCMC and James Chu, Senior Business Manager from AmoyDx
Key Highlights of the Initiative
Annual Overseas Molecular Pathology Training: Over the next 3 years, the VSPC will nominate top pathologists for an intensive three-month molecular pathology training program abroad where they will get the opportunity to learn and engage with global experts in the field.
Comprehensive Curriculum: An all rounded molecular pathology curriculum, covering both theoretical knowledge and its practical application in clinical settings. This will allow attendees to be exposed to international best practices as well as the ability to transfer valuable knowledge and experience back to the Vietnamese healthcare system.
About the Vietnam Society of Pathology and Cytology (VSPC): The VSPC is a professional organization dedicated to the advancement of pathology and cytology in Vietnam. It serves as a platform for Vietnamese pathologists and cytologists to exchange knowledge, foster professional development, and promote the highest standards of patient care in the field of pathology.
About AmoyDx: AmoyDx is at the forefront of championing molecular diagnostics for cancer, committed to enhancing patient outcomes worldwide through innovative diagnostic solutions and breaking barriers for global precision oncology adoption. The company is recognized for its excellence in precision medicine, driving advancements in cancer diagnosis through its extensive collaboration with pharmaceutical companies. For more information, please visit https://amoydiagnostics.com.
About BCE Vietnam: BCE Vietnam specializes in the distribution of life science, medical and diagnostic equipment, striving to introduce the latest healthcare innovations to the Vietnamese market. The company is dedicated to improving the quality of healthcare in Vietnam through state-of-the-art technologies and services. For more information, please visit https://bcevietnam.com.vn
For media inquiries, please contact:
Robson Ee
Director, International Business
AmoyDx(Singapore) PTE LTD
info@amoydiagnostics.com
https://www.amoydiagnostics.com
AmoyDx® PD-L1 (E1L3N) assay gained the priority recommendation from Chinese expert consensus
Next
Subscribe
to our
newsletter